Overview

An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia

Status:
Completed

Trial end date:
2014-09-01

Target enrollment:

Participant gender:

Summary

To evaluate the safety and efficacy of extended dosing with mipomersen (ISIS 301012) in participants with familial hypercholesterolemia or severe hypercholesterolemia on lipid-lowering therapy who had completed either the 301012-CS5 (NCT00607373), 301012-CS7 (NCT00706849), 301012-CS17 (NCT00477594) or MIPO3500108 (NCT00794664) clinical drug trials.

Phase:

Phase 3

Details

Lead Sponsor:

Kastle Therapeutics, LLC

Collaborator:

Ionis Pharmaceuticals, Inc.

Treatments:

Mipomersen